At the 2018 Annual Meeting of the American Society of Clinical Oncology
Glenmark Pharmaceuticals announced the presentation of data from two assets in its immuno-oncology portfolio at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). These presentations include preclinical and translational data on GBR 1302, a HER2xCD3 bispecific antibody, and a Trials in Progress (TIP) poster on GBR 1342, a CD38xCD3 bispecific antibody.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content